CBIO
Crescent Biopharma, Inc.
13.50$
-0.6%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -102.7% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -83.7% | +547.8% | -100.0% | +60,857.7% | -79.6% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -64.5% | -90.4% | -100.0% | – | |
| – | – | – | +28.0% | +0.7% | -0.7% | -1.2% | +1.2% | -1.6% | -0.2% | +3.1% | +1.1% | -0.6% | +222.6% | – | – | – | – | – | – | – | – | +0.9% | +0.1% | -0.9% | +1.4% | +1.3% | +1.1% | +1.5% | -91.4% | -37.2% | -15.0% | -34.6% | +232.6% | – | – | +81,300.0% | -96.7% | – | – | – | |
| – | -374.5% | – | – | – | – | – | – | – | – | – | – | – | – | – | -100.8% | – | -83.7% | +547.8% | -100.0% | +60,857.7% | -79.6% | -1,564.5% | – | -441.4% | – | – | – | – | – | -246.2% | – | – | – | – | – | – | -62.5% | -90.4% | – | – | |
| – | +2.3% | -3.0% | -2.7% | +1.0% | +16.3% | +34.3% | +3.1% | +4.6% | +23.7% | -2.2% | +11.0% | -17.9% | +6.9% | +10.5% | -22.1% | +8.1% | +9.8% | -4.9% | -8.8% | +30.6% | -2.9% | -25.5% | -17.0% | -38.3% | +19.7% | -8.0% | -24.8% | +29.9% | -0.1% | +13.9% | +4.3% | -72.7% | +718.1% | -24.3% | +13.7% | +68.4% | +367.0% | -81.2% | +8.3% | – | |
| – | +15.8% | -9.0% | -99.9% | +95,141.9% | +17.2% | +1.4% | -0.3% | -2.0% | +4.7% | +15.0% | +11.6% | -9.9% | +14.4% | +14.8% | -4.6% | -4.2% | -1.2% | +4.4% | +1.2% | -2.2% | +9.8% | +11.2% | +7.9% | -29.5% | +23.0% | +16.7% | -12.0% | -6.9% | -4.6% | +18.0% | -20.0% | -1.6% | -21.2% | +13.9% | +148.8% | -38.1% | +32.0% | +7.6% | +11.2% | – | |
| – | +5.7% | -4.6% | +3.4% | -0.8% | +16.6% | +24.5% | +2.3% | +3.1% | +19.5% | +1.2% | +11.1% | -16.1% | +8.7% | +11.6% | -17.5% | +4.4% | +6.8% | -2.5% | -6.1% | +21.0% | +0.1% | -16.0% | -8.4% | -34.7% | +21.2% | +3.0% | -18.4% | +9.9% | -2.2% | +15.8% | -6.8% | +8.5% | +53.0% | -17.3% | +47.8% | +23.1% | +295.3% | -74.8% | +2.3% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +30.5% | -3.5% | -100.0% | – | -100.0% | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -177.4% | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.